Listed

Astrana Health, Inc.

ASTHNasdaqCIK 1083446IndustrialsFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$972.5mRevenue, Q2 FY2026, three months to 2026-06-30$972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 10, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$972.5mRevenue, Q2 FY2026, three months to 2026-06-30$972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure+48.5% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin3.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $34.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Revenue: $972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure+0.4 pts on a year earlier
  • Net margin2.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $19.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Revenue: $972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure+0.6 pts on a year earlier
  • Diluted EPS$0.40Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure+110.5% on a year earlier
  • Free cash flow$28.9mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $32.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342631. Derived: 6-month figure less the 3-month figure.Capital expenditure: $3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342631. Derived: 6-month figure less the 3-month figure.Report this figure−67.7% on a year earlier

Last eight quarters

Full statements
Revenue$972.5mOperating margin 3.5%
Diluted EPS$0.40, Q2 FY2026
Free cash flow$28.9m, Q2 FY2026
Astrana Health, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m479Revenue, Q3 FY2024, three months to 2024-09-30$478.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figure665Revenue, Q4 FY2024, three months to 2024-12-31$665.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure620Revenue, Q1 FY2025, three months to 2025-03-31$620.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure655Revenue, Q2 FY2025, three months to 2025-06-30$654.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure956Revenue, Q3 FY2025, three months to 2025-09-30$956.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figure951Revenue, Q4 FY2025, three months to 2025-12-31$950.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure965Revenue, Q1 FY2026, three months to 2026-03-31$965.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure973Revenue, Q2 FY2026, three months to 2026-06-30$972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%5.9%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $28.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Revenue: $478.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figure0.1%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $720.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Revenue: $665.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure3.3%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $20.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Revenue: $620.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure3.1%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $20.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Revenue: $654.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure2.0%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $19.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Revenue: $956.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figure1.9%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $18.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Revenue: $950.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure3.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $28.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Revenue: $965.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure3.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $34.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Revenue: $972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure
Net margin%3.4%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $16.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Revenue: $478.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figure(1.0%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$7.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Revenue: $665.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure1.1%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Revenue: $620.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure1.4%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Revenue: $654.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure0.0%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $373.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Revenue: $956.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figure0.6%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $6.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Revenue: $950.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure1.5%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $14.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Revenue: $965.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure2.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $19.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Revenue: $972.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure
Diluted EPS$ per share0.33Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figurenot reported (Diluted EPS not reported)0.14Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure0.19Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure0.01Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-274359.Report this figurenot reported (Diluted EPS not reported)0.29Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure0.40Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342631.Report this figure
Free cash flow$m31.7Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $34.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-274359. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-274359. Derived: 9-month figure less the 6-month figure.Report this figure(13.5)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure13.6Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $16.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Capital expenditure: $3.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure89.5Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $90.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342631. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342631. Derived: 6-month figure less the 3-month figure.Report this figure7.4Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $10.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-274359. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-274359. Derived: 9-month figure less the 6-month figure.Report this figure(6.0)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Capital expenditure: $3.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-103128. Derived: 12-month figure less the 9-month figure.Report this figure64.1Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $68.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Capital expenditure: $4.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-08, accession 0001193125-26-213157.Report this figure28.9Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $32.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342631. Derived: 6-month figure less the 3-month figure.Capital expenditure: $3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342631. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$3.18bnOperating margin 2.5%
Diluted EPS$0.46, FY2025
Free cash flow$104.5m, FY2025
Astrana Health, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m774Revenue, FY2021, twelve months to 2021-12-31$773.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001628280-24-008024.Report this figure1,144Revenue, FY2022, twelve months to 2022-12-31$1.14bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0000950170-25-039122.Report this figure1,387Revenue, FY2023, twelve months to 2023-12-31$1.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure2,035Revenue, FY2024, twelve months to 2024-12-31$2.03bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure3,182Revenue, FY2025, twelve months to 2025-12-31$3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%12.7%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $98.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0001628280-24-008024.Revenue: $773.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001628280-24-008024.Report this figure9.1%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $104.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-14, accession 0000950170-25-039122.Revenue: $1.14bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0000950170-25-039122.Report this figure6.1%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $84.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128.Revenue: $1.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure4.4%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $89.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128.Revenue: $2.03bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure2.5%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $78.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128.Revenue: $3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure
Net margin%8.9%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $68.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0001628280-24-008024.Revenue: $773.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001628280-24-008024.Report this figure3.9%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $45.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-14, accession 0000950170-25-039122.Revenue: $1.14bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-14, accession 0000950170-25-039122.Report this figure4.4%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $60.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128.Revenue: $1.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure2.1%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $43.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128.Revenue: $2.03bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure0.7%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $22.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-103128.Revenue: $3.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure
Diluted EPS$ per share1.52Diluted EPS, FY2021, twelve months to 2021-12-31$1.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0001628280-24-008024.Report this figure0.99Diluted EPS, FY2022, twelve months to 2022-12-31$0.99 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-14, accession 0000950170-25-039122.Report this figure1.29Diluted EPS, FY2023, twelve months to 2023-12-31$1.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure0.90Diluted EPS, FY2024, twelve months to 2024-12-31$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure0.46Diluted EPS, FY2025, twelve months to 2025-12-31$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure
Free cash flow$m51.1Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $70.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0001628280-24-008024.Capital expenditure: $19.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0001628280-24-008024.Report this figure59.2Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $82.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-14, accession 0000950170-25-039122.Capital expenditure: $22.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-14, accession 0000950170-25-039122.Report this figure39.7Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $68.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-103128.Capital expenditure: $28.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure44.2Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $52.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-103128.Capital expenditure: $8.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure104Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $114.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-103128.Capital expenditure: $10.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-103128.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Astrana Health, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$320.2m6,899,990Added+736,263
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$120.9m2,605,775Added+328,969
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$90.3m1,946,431Added+236,169
STATE STREET CORP2026-06-30$80.7m1,738,930Added+88,440
325 CAPITAL LLC2026-06-30$74.9m1,613,843Reduced−225,233
DIMENSIONAL FUND ADVISORS LP2026-06-30$68.1m1,468,508Added+100,429
WELLINGTON MANAGEMENT GROUP LLP2026-06-30$60.0m1,292,573Reduced−49,251
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$54.2m1,167,974Added+129,889
BANK OF AMERICA CORP /DE/2026-06-30$39.5m852,145Added+277,416
FMR LLC2026-06-30$31.8m685,922Added+269,797

Recent filings

All 966 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Astrana Health, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-2312:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-109822
2026-09-2311:30 ET8-K1.05 Material cybersecurity incident0001104659-26-109813
2026-09-1512:45 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-107730
2026-08-1021:03 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-342631
2026-08-0620:11 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-092003
2026-07-1312:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-082892
2026-07-0120:15 ET8-K5.02 Departure or appointment of officers or directors0001104659-26-079874
2026-06-1020:15 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-26-072343
2026-05-1210:06 ET8-K5.02 Departure or appointment of officers or directors0001104659-26-058922
2026-05-1210:03 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-058914

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 12, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1083446
Tickers
ASTH
Exchange
Nasdaq
SIC code
8742 Services-Management Consulting Services
Sector
Industrials
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
Apollo Medical Holdings, Inc. (to 2024-02-13); SICLONE INDUSTRIES INC (to 2008-07-15)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:32 ET. Listed shows no prices and gives no investment advice.